3 months Premium FREE
No credit card. No commitment.
AstraZeneca PLC
🇬🇧 AZN.LSE · London · GB0009895292
Healthcare
Scores
Key Metrics
Powered by EODHDP/E (TTM)
18.2
P/E (Price-to-Earnings)Shows how much investors pay for each $1 of profit. We display the TTM P/E (Trailing Twelve Months) which uses actual earnings from the last 4 quarters. This is more reliable than Forward P/E which uses analyst estimates.
Net Debt/EBITDA (TTM)
1.3x
Latest quarter: 5.5x
Net Debt / EBITDAA leverage ratio showing how many years of EBITDA (earnings before interest, taxes, depreciation, and amortization) it would take to repay net debt. EBITDA approximates operating cash generation. Lower ratios (e.g., <3x) are generally safer; higher (e.g., >5x) may indicate more financial risk.
Latest quarter (2026-06-30): 5.5x
The quarterly value can spike when quarterly EBITDA is very low (e.g., one-time charges).
Quick guide: <2x manageable, >4x can be risky (sector-dependent).
ROE
22.0%
ROE (Return on Equity)A profitability measure: how much profit is generated from shareholders’ equity. Higher isn’t always better if it comes from high debt.
EV/EBITDA
13.8x
EV/EBITDAA valuation ratio that compares total business value (including debt) to EBITDA. Lower can mean cheaper, but context matters.
Dividend Summary
Powered by EODHDDividend Yield (Fwd)
1.78%
TTM: 1.96%
Dividend YieldThe Forward yield (Fwd) shows the next announced annual dividend / current price — what you'd earn going forward. The Trailing yield (TTM) in the tooltip shows dividends actually paid in the last 12 months. Forward is shown as primary because it reflects the company's current commitment to shareholders.
Forward Yield (estimated): 1.78%
Trailing Yield (TTM, last 12 months): 1.96%
Payout Ratio (Fwd)
24.6% TTM
Payout RatioDividends as a percentage of earnings. The Forward payout (Fwd) uses the announced dividend divided by actual past earnings (TTM) — it tells you if the company can afford what it promised. Very high payouts can be risky, especially if profits fall.
Announced dividend / actual earnings (TTM)
Dividend History
EODHD Dividends API| Status | Type | Decl. Date | Ex-Div Date | Pay Date | Currency | Amount |
|---|---|---|---|---|---|---|
| Forecast* | Interim | — | 06 Aug 2027 | — | GBP | 0.795 |
| Forecast* | Final | — | 19 Feb 2027 | — | GBP | 1.595 |
| Declared | Interim | 10 Feb 2026 | 06 Aug 2026 | 08 Sep 2026 | GBP | 0.795 |
| Paid | Final | 10 Feb 2026 | 19 Feb 2026 | 23 Mar 2026 | GBP | 1.595 |
* Extrapolated from past dividend history. Not an official announcement — treat as an estimate, not a confirmed date or amount.
Summary
AstraZeneca is a high-quality global biopharmaceutical leader demonstrating excellent profitability, a deleveraged balance sheet, and a highly secure dividend. However, the low 1.96% yield, elevated valuation, and looming structural patent cliffs limit its immediate DGI appeal. Existing holders should maintain positions based on pipeline strength, but it remains a WATCH for new income-focused capital.
Sector Context
Healthcare / Drug Manufacturers. Large-cap pharmaceutical companies typically offer recession-resistant cash flows and strong margins. However, they require constant R&D success to outpace inevitable patent cliffs and biosimilar erosion. DGI strategies typically demand higher baseline yields to offset this pipeline risk.
Temporary Opportunity Identified
Short-term market sentiment is pressured by ongoing China fraud investigations, recent antitrust litigation settlements (e.g., Seroquel), and transient mega-merger rumors. However, the core business faces concurrent structural patent cliffs.
📊 Strategy Analysis
- • Exceptional financial stability, with Net Debt/EBITDA deleveraged to 1.34x and a robust ROE of 21.9%.
- • Highly secure dividend with a low FCF payout ratio of 35.7% and strong 1.72x FCF dividend coverage.
- • Solid underlying business momentum, demonstrating a 5-year revenue CAGR of 9.6% driven by strong oncology pipeline readouts.
⚠ What to Watch
- • Low current dividend yield of 1.96% falls significantly below standard DGI income targets, paired with a mixed historical dividend growth record (1.4% overall CAGR).
- • Current valuation remains elevated with a TTM P/E of 18.21, sitting above the optimal strategy range.
- • Major structural headwinds are actively materializing, including the U.S. patent expiration for blockbuster Farxiga (April 2026) and ongoing Soliris biosimilar erosion.
- • Ongoing systemic fraud investigations into AstraZeneca's Chinese subsidiary introduce near-term legal, reputational, and regional market share risks.
📊 Historical Trends (10 Years)
Powered by EODHDThese charts show how key metrics have evolved over the past decade, helping you identify if the company is improving or deteriorating.
Debt Evolution (Net Debt / EBITDA)
Lower values are better. A declining trend indicates the company is reducing its debt (deleveraging).
Revenue & Earnings Growth
Consistent growth in revenueRevenue
The money a company brings in from selling its products or services. It’s the top line before costs. (blue) and earningsEarnings (Profit)
What’s left after expenses. Positive earnings mean the business made a profit; negative means a loss. (green) indicates a healthy business. Look for upward trends and recoveries after temporary dips.
Dividend Sustainability (FCF vs Dividends Paid)
Free cash flowFree Cash Flow
Cash left after the company pays for running the business and maintaining it. Often used to fund dividends, pay debt, or buy back shares. (FCFFCF (Free Cash Flow)
Short for Free Cash Flow: cash left after operating needs and maintenance spending., blue) should cover dividends paidDividends Paid
Cash the company paid out to shareholders. It’s not guaranteed and can change over time. (green). If dividends consistently exceed FCFFCF (Free Cash Flow)
Short for Free Cash Flow: cash left after operating needs and maintenance spending., the dividend may be at risk.
Analysis date: 2026-08-22
Disclaimer: This information is for educational purposes only. Not financial advice.